Study On The Mechanism Of Jiedu Sanjie Recipe In The Treatment Of Liver Cancer Based On Network Pharmacology
Abstract
Objective: to study the mechanism of action of Jiedu Sanjie Recipe in the treatment of Liver Cancer through network pharmacology. Method: Collect and screen the active ingredients of Jiedu Sanjie Recipe through the Traditional Chinese Medicine System Pharmacology Database and Analysis Platform (TCMSP), and search for the human target protein corresponding to the active ingredients in the database; screen out the target set of liver cancer-related diseases through GeneCards and OMIM database; construct a Venn diagram to obtain the key target of Jiedu Sanjie Recipe for treating liver cancer; use Cytoscape 3.8.0 software to construct drug-component-target-pathway network; use Cytoscape software and BisoGenet plug-in to construct protein interaction network, use CytoNCA plug-in and R language to perform network topology analysis, gene ontology functional annotation (GO) and KEGG rich Collect pathway analysis to understand the possible biological processes and pathways of Jiedu Sanjie Decoction in treating liver cancer. Results: A total of 89 active ingredients of Jiedu Sanjie Prescription, 170 targets and 1885 liver cancer targets were obtained; After mapping, 114 potential targets of Jiedu Sanjie Recipe for liver cancer are obtained, and the core active ingredients are quercetin, luteolin, kaempferol, wogonin, baicalein, etc. The core targets NTRK1, TP53, CUL3, ESR1, MCM2, etc., involving lipids and atherosclerosis, chemical carcinogenesis-receptor activation signaling pathways, Ka_x005fposi’s sarcoma-associated herpes virus infection, fluid shear stress and atherosclerosis Cirrhosis, hepatitis C, AGE-RAGE signaling pathway, hepatitis B, human cytomegalovirus infection, cancer proteoglycan, TNF signaling pathway, IL-17 signaling pathway, etc.Conclusion: This study reveals the mechanism of the multi-component, multi-target, and multi-channel treatment of liver cancer by “Knowing Du Sanjie Decoction”, and provides a basis for the clinical application of Chinese medicine prescriptions for liver cancer.
References
[1] Guidelines for diagnosis and treatment of primary liver cancer in China ( 2019 edition) [J]. Journal of Clinical Hepatolo_x005fgy,2020,36(02):277-292.
[2] REN Shuang, NI Li-qiang, MENG Di, et al. Mechanisms of Cortex phellodendri-Herba tuberculate speranskia in treatment of rheumatoid arthritis based on network pharmacology [J].
Chinese Journal of New Drugs and Clinical Remedies,2019,38(12):757-766.
[3] Mlcek J, Jurikova T, Skrovankova S, et al. Quercetin and Its Anti-Allergic Immune Response.
[J]. Molecules (Basel, Switzerland),2016,21(5):623.
[4]WANG Zi-xuan, ZHOU Jing, TANG Yue, et al. Quercetin induces P53-independent G2/M arrest and apoptosis in cancer cells [J].
Chinese Journal of Pharmacology and Toxicology,2018,32(10):790-796.
[5]Yang Peiwei, Zhang Shuhui. Advances in the study of the effect and mechanism of Luteolin on
hepatocellular carcinoma [J]. Pharmacology and Clinics of Chinese Materia Medica,2018,34(01):190-193.
[6]Guo Haiqing, Liu Yali, Ren Feng, et al. Research on the effect of kaempferol on HepG2 apoptosis and its mechanism [J]. Beijing
Medical Journal,2021,43(09):899-904.
[7]Zhong Nan, Li Qin, Feng Yanhong, et al. Research advances in wogonin’s anti-tumor effects [J]. Clinical Misdiagnosis & Mistherapy,2019,32(11):112-116.
[8]LEI Boting, MA Chaoying. Research Progress on Anti-Hepatocarcinoma of Berberine [J]. Chinese Archives of Traditional Chinese
Medicine,2014,32(02):254-256.
[9]Liu Peiyi. Mitochondrial homeostasis and mitophagy in hepatic steatosis: regulation of quercetin through Frataxin [D]. Huazhong
University of Science and Technology,2018.
[10].Deng M , Sun J , Xie S , et al. Inhibition of MCM2 enhances the sensitivity of ovarian cancer
cell to carboplatin[J]. Molecular Medicine Reports, 2019, 20(3).
[11]ZHANG Xia, LIU Jian-ying. AGES-RAGE system and anti-tumor effect of metformin [J]. Chinese Journal of New
Drugs,2014,23(04):441-444.
[12]LU Gan-shan, SHI Guang-ying, QI Ying-chao, et al. Determination Analysis of Serum IGF-1, IL-17 and AFP Levels of Primary
Liver Cancer Patients [J]. World Latest Medicine Information,2018,18(46)：8-9.
[13]ZHANG Geng, LIU Guangzhao, FENG Guiyin, et al. Correlation Analysis on the Relationship between Pain and Serum HlF-1 and
VEGF Levels in Patients with Primary Liver Cancer [J]. Hebei Medicine,2019,25(03):615-618.
[14]CAO Jian, ZHU Xiao-ran, YANG Zhen-huan, et al. An exploration on mechanisms of Qinggan Huayu Granule in treating liver
cancer based on network pharmacology [J]. Chinese Traditional and Herbal Drugs,2021,52(07):2039-2052.
Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear
Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.
